Go back to Healthcare Systems
Unlocking the Dark Genome for Lupus and Other Autoimmune Diseases
Cambridge Associates
Autoimmune diseases like lupus impact over 5 million patients globally, but treatment options remain limited. However, by decoding the once mysterious “dark genome,” new therapies could be possible.
At one point, 98% of our DNA was considered “junk” and therefore not studied. Since then, we’ve learned that this “junk DNA” actually regulates gene expression and human disease. Now coined the “dark genome,” this episode takes you to the pioneers who are unlocking its potential to correct root causes of complex conditions like lupus. We’ll chat with those illuminating this uncharted territory and developing novel approaches, including:
- Rosana Kapeller, M.D., Ph.D., Co-Founder, President, & CEO at Rome Therapeutics
- Steve Kafka, General Partner at S32
- Keri Mastrogiacomo, mother of a Lupus patient
- Katherine Cavanagh, Associate Investment Director at Cambridge Associates
Listen below or wherever you get your podcasts.
